A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line treatment for nonsmall-cell lung cancer (NSCLC) patients with an activating EGFR mutation. Osimertinib, compared with erlotinib or gefitinib, showed an improvement in progression-free s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jia-Zhou, Ma, Song-Kun, Wu, Sheng-Xi, Yu, Shu-Han, Li, Xu-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078751/
https://www.ncbi.nlm.nih.gov/pubmed/30045282
http://dx.doi.org/10.1097/MD.0000000000011569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078751/
https://www.ncbi.nlm.nih.gov/pubmed/30045282
http://dx.doi.org/10.1097/MD.0000000000011569

Ejemplares similares